{
    "id": "0793fd3b-1fa1-4ef3-ae2f-756ef19ecc56",
    "indications": "Tranexamic acid in 0.7% sodium chloride injection is indicated in patients with hemophilia for short-term use (two to eight days) to reduce or prevent hemorrhage and reduce the need for replacement therapy during and following tooth extraction.",
    "contraindications": "Before Extraction: Administer 10 mg/kg actual body weight of tranexamic acid in 0.7% sodium chloride injection intravenously with replacement therapy. After Extraction: Administer 10 mg/kg actual body weight 3 to 4 times daily for 2 to 8 days. Infuse no more than 10 mL/minute to avoid hypotension. ( 2.1 ) Reduce the dosage for patients with renal impairment. ( 2.2 , 8.6 )",
    "warningsAndPrecautions": "Tranexamic Acid in 0.7% Sodium Chloride Injection, 1,000 mg per 100 mL (10 mg per mL) is supplied as a sterile, unpreserved, clear, colorless solution in a single-dose polymeric bag containing 1,000 mg tranexamic acid in 100 mL of solution sealed with a Twist-off port and oversealed in an aluminum pouch.\n                  It is available as follows:\n                  \n                     \n                     \n                     \n                     \n                        \n                           \n                              \n                                 Strength\n                              \n                           \n                           \n                              \n                                 Each\n                              \n                           \n                           \n                              \n                                 Unit of Sale\n                              \n                           \n                        \n                        \n                           \n                              \n                                 \n                                    1,000 mg per 100 mL\n                                 \n                              \n                              (10 mg per mL)\n                           \n                           \n                              NDC 80830-2329-1\n                              1 Single-dose Infusion Bag in an Overwrap\n                           \n                           \n                              NDC 80830-2329-2\n                              Unit of 10\n                           \n                        \n                        \n                            \n            NDC 80830-2329-3\n            Unit of 12\n                        \n                     \n                  \n                  Store at 20° to 25°C (68° to 77°F); excursions permitted between 15° to 30°C (59° to 86°F) [see USP Controlled Room Temperature]. Discard any unused portion.",
    "adverseReactions": "Tranexamic acid in 0.7% sodium chloride injection is contraindicated: \n                  \n                     In patients with subarachnoid hemorrhage. Anecdotal experience indicates that cerebral edema and cerebral infarction may be caused by tranexamic acid in such patients. \n                     In patients with active intravascular clotting [see Warnings and Precautions (5.1)].\n                     In patients with hypersensitivity to tranexamic acid or any of the ingredients [see Warnings and Precautions (5.3)].",
    "ingredients": [
        {
            "name": "TRANEXAMIC ACID",
            "code": "6T84R30KC1"
        },
        {
            "name": "SODIUM CHLORIDE",
            "code": "451W47IQ8X"
        },
        {
            "name": "WATER",
            "code": "059QF0KO0R"
        }
    ],
    "organization": "Amneal Pharmaceuticals Private Limited",
    "name": "TRANEXAMIC ACID IN SODIUM CHLORIDE",
    "effectiveTime": "20231130"
}